Bendamustin Market Size, Share & Industry Analysis, By Dosage Form (Liquid, {100-mg injection, 25mg injection}, Lyophilized), By Application (Chronic Lymphocytic Leukemia, Non-Hodgkins Lymphoma, Multiple Myeloma), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Others) and Regional Forecast, 2024-2032

Bendamustin is a nitogen-mustard drug indicated for use in treatmemt of chronic lymphocytic leukemia, Non-Hodgkin’s lymphoma, and multiple myeloma. It works by killing the cancer cells or slowing their growth, however, the exact mechanism of bendamustin is unknown. It is given intravenously and is availablle in liquid and lyphilized dosage forms. Growing prevalence of chronic lymphocytic leukemia, Non-Hodgkin’s lymphoma, and multiple myeloma; growing awareness among the population, various initiatives by the governmental and non-governmental organisation in improving the healthcare in developed and developing regions, and numerous product launches by the market players are the factors contributing in driving the market growth during the forecast period.  For instance, in May 2018, Eagle Pharmaceuticals, Inc., received the USFDA approval for its ready-to-dilute (RTD) bendamustine hydrochloride (HCl) solution in a 500 ml for the treatment of patients with chronic lymphocytic leukemia and Non-Hodgkin’s lymphoma

The bendamustin market is expected to register a considerable market growth during the forecast period due to factors such as growing prevalence of chronic lymphocytic leukemia, Non-Hodgkin’s lymphoma, and multiple myeloma, growing awareness among the population, and various initiatives by the governmental and non-governmental organization in improving the healthcare in developed and developing regions. However, various side-effects associated with the drug such as vomiting, diarrhea, fever, weight loss, etc. is one of the major factors likely to restrict the growth of bendamustin market.

Key Market Driver -

Rising prevalence of chronic lymphocytic leukemia, Non-Hodgkin’s lymphoma, and multiple myeloma

Key Market Restraint -

Side effects associated with the drug and limited awareness among the population about available treatments

Market Segmentation:

Globally, the bendamustin market can be segmented on the basis of the dosage form, application, distribution channel, and region. Based on the dosage from, the market can be segmented into liquid and lyophilized. Based on the liquid form, the market can be further segmented into 100-mg injection and 25mg injection. Based on application, the market can be segmented into chronic lymphocytic leukemia, Non-Hodgkin’s lymphoma, and multiple myeloma. Based on the distribution channel, the market can be segmented into hospitals pharmacies, retail pharmacies, and others. Geographically, the bendamustin market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

Key Players Covered:

Some of the major companies that are present in the bendamustin market are Teva Pharmaceutical Industries Ltd., Eisai Co., Ltd., Mundipharma International., Mylan N.V., NATCO Pharma Limited., Emcure Pharmaceuticals Ltd, Eagle Pharmaceuticals, Inc., and other prominent players.

Key Insights:

• Key Industry Trends


• New Product Launches


• Key Industry Developments Mergers, Acquisitions, And Collaborations

Regional Analysis:

Geographically, the bendamustin market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to lead the Bendamustin market with the largest market share throughout the forecast period. The growing prevalence of chronic lymphocytic leukemia, Non-Hodgkin’s lymphoma, and multiple myeloma is likely to augment the market growth of this region. For instance, according to National Cancer Institute, in 2017, there were an estimated 186,422 people living with chronic lymphocytic leukemia in United States. Europe is likely to hold second largest bendamustin market share attributable to the growing demand of bendamustin due to the increasing patient population of chronic lymphocytic leukemia. On the flip side, the market in Asia Pacific is projected to expand at the highest CAGR on account of empowered healthcare industry and growing incidences of chronic lymphocytic leukemia, Non-Hodgkin’s lymphoma, and multiple myeloma.

To gain extensive insights into the market, Request for Customization

The market in Latin America and the Middle East & Africa are expected to have a slower growth rate. However, improving healthcare sector in these regions is contributing in expanding growth rate of the market.

Segmentation

Bendamustin Market Industry Developments

• In May 2018, Eagle Pharmaceuticals, Inc., received the USFDA approval for its ready-to-dilute (RTD) bendamustine hydrochloride (HCl) solution in a 500ml for the treatment of patients with chronic lymphocytic leukemia and Non-Hodgkin’s lymphoma.


• In December 2015, Teva Pharmaceutical Industries Ltd. and Eagle Pharmaceuticals, Inc. received the USFDA approval for BENDEKA (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine.